Close Menu

NEW YORK (360Dx) – Immunodiagnostics firm Singulex announced today that it has formed a strategic collaboration with Qiagen to develop companion diagnostics.

Under the terms of the deal, Qiagen will combine Singulex's single-molecule counting (SMC) technology with its own molecular testing services to develop companion diagnostics. Qiagen will also have access to Singulex's CLIA lab. The companies aim to collaborate in a range of disease applications, Singulex said.

Additional terms were not disclosed.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Dec
05
Sponsored by
Amazon

The discovery of microbial cell-free DNA has propelled the introduction of new technologies that can be leveraged for next-generation diagnostic assays. Previously inaccessible genomic information can now be comprehensively surveyed for microorganisms, all from a single blood draw.